GET DAILY SIGNALSWhy Is Pluri (PLUR) Stock Up +6.72% Today?
Key Takeaways
- PLUR shares are up roughly 6.7% intraday, trading near $1.27 versus a prior close of $1.19.
- The advance extends a rally sparked by the company's strategic partnership with ZEO ScientifiX (ZEOX).
- Insider buying and a show of confidence from Chairman Alejandro Weinstein are underpinning sentiment.
- Broad strength across small- and micro-cap biotech names is adding momentum to the move.
- Traders are watching the company's Oct. 29 investor conference call and the partnership's targeted Q4 close.
- Explore detailed Price Targets, Earnings, and Forecast pages for PLUR.
- Discover the strongest-performing strategies on Tickeron's Trending AI Robots page.
Opening Summary
Pluri Inc. (PLUR), a Haifa, Israel–based biotechnology company advancing cell-based products through its proprietary 3D cell-expansion platform across cell therapy, contract manufacturing, and food technology, is trading sharply higher in Wednesday's session. The stock is up approximately 6.7%, changing hands near $1.27 compared with a prior closing price of $1.19. Markets attribute the move to continued enthusiasm around the company's newly announced U.S. regenerative-medicine partnership, reinforced by insider activity and favorable momentum across the small-cap biotech sector.
ZEO ScientifiX Partnership Drives the Rally
The primary catalyst remains PLUR's definitive strategic agreement with ZEO ScientifiX (ZEOX), announced on Oct. 26, to build a combined U.S. manufacturing and commercialization platform for regenerative medicine, aesthetics, wellness, and longevity markets. Under the deal, Pluri contributes its proprietary 3D cell-expansion technology and clinical-development expertise, while ZEO provides an established biologics portfolio, physician network, and sales and marketing infrastructure. The transaction includes exclusive U.S. rights to Pluri's Cellav aesthetic product line and is expected to result in Pluri owning 50% of ZEO at closing, targeted for the fourth quarter of 2026. The announcement triggered a multi-day advance that is carrying into today's trading.
Insider Confidence and Financing Signals
Supporting sentiment, insider filings showed a 10%-plus shareholder adding roughly 833,000 shares in late October, while Chairman and largest shareholder Alejandro Weinstein separately agreed to acquire the company's European Investment Bank loan — a move framed by the company as a strong vote of confidence. These signals of insider conviction, combined with the strategic partnership, have helped shift near-term investor perception for a stock that had been trading below its August $1.50 registered-direct-offering price.
Sector Momentum and Market Reaction
The price rally is also benefiting from broader strength in small- and micro-cap biotechnology names, where speculative capital has rotated toward companies announcing fresh commercial or strategic developments. PLUR's move has aligned with gains across several peers in the biotech space, amplifying the stock's momentum as investors position ahead of the company's upcoming investor communications.
Market Context and Trading Activity
Trading volume has been elevated relative to PLUR's typical daily average of roughly 30,000 shares, with the partnership announcement drawing a pronounced multi-day surge in activity. The stock is trading well above its 52-week low of $0.85 yet remains below its 52-week high of $4.87 and below the $1.50 level at which the company priced its August direct offering. The move reflects company-specific news rather than a broad-market catalyst, with the biotech sub-sector outperforming the broader tape this week.
What Comes Next for PLUR
Investors are turning attention to PLUR's online investor conference call scheduled for Oct. 29, where management is expected to discuss updates and strategic developments, as well as the targeted Q4 2026 closing of the ZEO ScientifiX transaction. Upcoming earnings and the company's next quarterly report will be closely watched for updates on cash runway and operating progress. Key risks include the auditor's going-concern language in the latest annual report, limited cash resources, the past-due European Investment Bank loan, and the need to regain Nasdaq's minimum market-value requirement. The regulatory approval and integration of the ZEO partnership also carry execution risk.
Trending AI Robots
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing traders to follow automated approaches that match their own risk preferences and objectives. Explore the page to see which AI-driven strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PLUR's RSI Indicator ascending out of oversold territory
The RSI Oscillator for PLUR moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 25 of the 29 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 62 cases where PLUR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on PLUR as a result. In 84 of 108 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for PLUR just turned positive on October 01, 2026. Looking at past instances where PLUR's MACD turned positive, the stock continued to rise in 40 of 51 cases over the following month. The odds of a continued upward trend are 78%.
PLUR moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +9.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where PLUR advanced for three days, in 166 of 219 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLUR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PLUR broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PLUR entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.665) is normal, around the industry mean (3.162). P/E Ratio (-0.508) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (10.650) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. PLUR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PLUR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Is There Anything Else I Need to Know About Bonds?
What Is the Sharpe Ratio?
What Led to the Decline of J.C. Penney's Stock?
Harnessing the Power of the Broadening Top (Bullish) Pattern in Stock Trading
How to Trade Energy Stocks During War: AI Robot with 62% Win Rate & +strong performance Crushes SPY While Oil Surges to $150/bbl
General Information
a developer of stem cell production technology
Industry Biotechnology
Advertisement